FMP
Entera Bio Ltd.
ENTX
NASDAQ
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
2.34 USD
0.11 (4.7%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
236k
365k
571k
134k
-
-
-
-
-
-
-
54.66
56.44
-76.53
-100
-16.36
-16.36
-16.36
-16.36
-11.35M
-11.11M
-12.16M
-12.87M
-8.8M
-
-
-
-
-
-4.81k
-3.04k
-2.13k
-9.6k
100
-60
-60
-60
-60
-11.58M
-11.17M
-12.22M
-12.93M
-8.86M
-
-
-
-
-
-4.91k
-3.06k
-2.14k
-9.65k
100
-60
-60
-60
-60
238k
63k
53k
64k
56k
-
-
-
-
-
100.85
17.26
9.28
47.76
100
54.86
54.86
54.86
54.86
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)